Objectives: To estimate the comparative efficacy of cladribine tablets versus alternative disease modifying therapies (DMTs) – fingolimod, natalizumab, alemtuzumab and ocrelizumab – in adults with active relapsing–remitting multiple sclerosis (RRMS), using meta-regression to provide subpopulation-specific estimates of drug effect. Additionally, to determine the feasibility of conducting a matching-adjusted indirect comparison (MAIC) to validate the meta-regression results. Methods: A published systematic literature review (SLR) identified studies evaluating the efficacy of cladribine tablets and alternative DMTs in the management of active RRMS. A series of meta-regression models were run with adjustment for baseline risk, fitted to data fr...
Background Multiple sclerosis (MS) is a chronic disabling disease that is associated with negative e...
Background: Cladribine tablets (marketed as Mavenclad) are a new oral therapy, which has recently be...
Background: Cladribine tablets (marketed as Mavenclad) are a new oral therapy, which has recently be...
<p><b>Objective:</b> To assess the comparative efficacy and safety of cladribine tablets versus alte...
OBJECTIVE: Cladribine tablets were tested against placebo in randomized controlled trials (RCTs). In...
Background: Effectiveness of cladribine tablets, an oral disease-modifying treatment (DMT) for multi...
BACKGROUND: Effectiveness of cladribine tablets, an oral disease-modifying treatment (DMT) for multi...
OBJECTIVE: This propensity score-matched analysis from MSBase compared the effectiveness of cladribi...
Objective: This propensity score–matched analysis from MSBase compared the effectiveness of cladribi...
Background Since 2010, 27 mixed-treatment comparisons (MTCs) of disease-modifying therapies (DMTs) f...
Background: Cladribine tablets are a highly effective immune reconstitution therapy licensed for tre...
Background Multiple sclerosis (MS) is a chronic disabling disease that is associated with negative e...
Background: Cladribine tablets (marketed as Mavenclad) are a new oral therapy, which has recently be...
Background: Cladribine tablets (marketed as Mavenclad) are a new oral therapy, which has recently be...
<p><b>Objective:</b> To assess the comparative efficacy and safety of cladribine tablets versus alte...
OBJECTIVE: Cladribine tablets were tested against placebo in randomized controlled trials (RCTs). In...
Background: Effectiveness of cladribine tablets, an oral disease-modifying treatment (DMT) for multi...
BACKGROUND: Effectiveness of cladribine tablets, an oral disease-modifying treatment (DMT) for multi...
OBJECTIVE: This propensity score-matched analysis from MSBase compared the effectiveness of cladribi...
Objective: This propensity score–matched analysis from MSBase compared the effectiveness of cladribi...
Background Since 2010, 27 mixed-treatment comparisons (MTCs) of disease-modifying therapies (DMTs) f...
Background: Cladribine tablets are a highly effective immune reconstitution therapy licensed for tre...
Background Multiple sclerosis (MS) is a chronic disabling disease that is associated with negative e...
Background: Cladribine tablets (marketed as Mavenclad) are a new oral therapy, which has recently be...
Background: Cladribine tablets (marketed as Mavenclad) are a new oral therapy, which has recently be...